Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.
Advertisement

Related Content

Resveratrol Partners Asks For IND Waiver On Macular Degeneration Claim
ChromaDex Looks To Pharma Model For Commercializing Supplement Research
Verastem Joins The Public Markets With A Strong IPO
National Advertising Division In Brief
Glaxo finds execs selling resveratrol supplements
New Products In Brief
Advertisement
UsernamePublicRestriction

Register

PS104827

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel